Protagonist Therapeutics (NASDAQ: PTGX) net income
Protagonist Therapeutics reported a net loss of $130.1m for fiscal 2025; in fiscal 2024 it reported a net profit of $275.2m. Earnings per share were −$2.05.
Protagonist Therapeutics's best year of the last 10 was fiscal 2024. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$130.1m | −147.3% | −282.8% | −$2.05 |
| 2024 | $275.2m | — | 63.3% | $4.47 |
| 2023 | −$79.0m | — | −131.6% | −$1.39 |
| 2022 | −$127.4m | — | −479.3% | −$2.60 |
| 2021 | −$125.6m | — | −458.9% | −$2.71 |
| 2020 | −$66.2m | — | −231.1% | −$1.92 |
| 2019 | −$77.2m | — | −33,414.3% | — |
| 2018 | −$38.9m | — | −125.9% | — |
| 2017 | −$37.0m | — | −184.2% | — |
| 2016 | −$37.2m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Protagonist Therapeutics net income compared with its sector
By net income for its latest fiscal year, Protagonist Therapeutics ranks 363rd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Protagonist Therapeutics, −282.8%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 361st | Jade Biosciences | −$127.4m | — |
| 362nd | ORIC Pharmaceuticals | −$129.5m | — |
| 363rd | Protagonist Therapeutics | −$130.1m | −282.8% |
| 364th | Cartesian Therapeutics | −$130.3m | −4,658.6% |
| 365th | Maravai LifeSciences | −$130.8m | −70.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Protagonist Therapeutics
- How much did Protagonist Therapeutics earn in fiscal 2025?
- Protagonist Therapeutics reported a net loss of $130.1m for fiscal 2025. In fiscal 2024 it reported a net profit of $275.2m.
- What are the earnings per share of Protagonist Therapeutics?
- They were −$2.05 in fiscal 2025, compared with $4.47 in fiscal 2024.
- What was the most profitable year for Protagonist Therapeutics?
- Of its last 10 fiscal years, fiscal 2024, with $275.2m.
- Where does Protagonist Therapeutics rank in its sector by net income?
- It ranks 363rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Protagonist Therapeutics come from?
- From the annual report (Form 10-K) that Protagonist Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Protagonist Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Protagonist Therapeutics: the Protagonist Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.